Home

The content presented here was prepared by independent authors under the editorial supervision of Creative Educational Concepts, Inc. and does not represent a publication of the American Society of Clinical Oncology. These materials are not sanctioned by ASCO and do not constitute an official part of that meeting.

Target Audience
This activity has been designed to benefit medical oncologists, oncology nurses, and other healthcare providers who manage or treat patients with cancer-related bone health issues.

Statement of Need
Bone health is often compromised for cancer patients as a result of treatment related loss of bone-mineral density or bone metastases. Current strategies to manage complications of bone metastases and treatment related loss of bone-mineral density are less than optimal and providing oncology professionals with timely, conference coverage on emerging clinical trial data on bone health supportive care strategies is imperative in order to improve patient health outcomes. The results of multiple and varied cancer research studies are presented each year at the American Society of Clinical Oncology (ASCO) annual meeting. This activity will enable participants to receive information that was presented at the much larger society meeting, in a smaller forum. Patterns of practice have the potential to change based on new data, and the accessibility to this overview allows participants to remain informed.

Educational Objectives
Upon completion of this activity, participants should be better able to:

• Categorize side effects and safety profiles of bone health management strategies.
• Evaluate published data based on study design, the reported results, and authors’ conclusions.
• Consider the reviewed data as it relates to previous, current and future treatment.

Faculty Information

Matthew R. Smith, MD, PhD Director of Research, Genitourinary Unit of Oncology Massachusetts General Hospital Cancer Center Assistant Professor of Medicine Harvard Medical School Boston, Massachusetts

Biography
Matthew R. Smith, MD, PhD, a board certified specialist in internal medicine and medical oncology, is an Assistant Professor of Medicine at Harvard Medical School in Boston, Massachusetts, and Director of Research for the Genitourinary Unit of Oncology at Massachusetts General Hospital Cancer Center in Boston.

Dr. Smith received his medical degree from Duke University School of Medicine in Durham, North Carolina, and his doctorate in molecular biology from Duke University Graduate School. He completed an internship and residency in internal medicine at Brigham and Women's Hospital in Boston, a clinical fellowship in medical oncology at the Dana-Farber Cancer Institute in Boston, Massachusetts, and a fellowship in molecular biology at Massachusetts Institute of Technology in Cambridge, Massachusetts.

A three-time recipient of the CaP Cure Prostate Cancer Research Award and a past recipient of the Clinical Associate Physician Award from the National Institutes of Health (NIH) and the Doris Duke Charitable Foundation Clinical Scientist Award, Dr. Smith's work focuses on understanding and preventing the side effects of hormonal therapy in men with prostate cancer, and the treatment of bone metastasis. His research has been published in such medical journals as the New England Journal of Medicine, Journal of Clinical Oncology, Cancer, Urology, Hematology/Oncology Clinics of North America, and the Journal of Urology. He has also contributed to a number of medical textbooks.

Dr. Smith is a member of the American Society of Clinical Oncology, the American Society for Bone and Mineral Research, and the American Urologic Association.

Instructions
To receive a statement of credit, you must:

• Review the full content of the activity and reflect upon its teachings
• Complete the questions and evaluation at the end of the activity

Accreditation

Medicine

Creative Educational Concepts, Inc. (CEC) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. CEC designates this educational activity for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nursing
CEC is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. CEC provides this activity for .50 contact hours.

Fee
This activity is complimentary.

Disclosure Declaration
It is the policy of CEC ensure independence, balance, objectivity, scientific rigor, and integrity in their continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems. Fair balance is achieved through ongoing and thorough review of all presentation materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by CEC of any product or manufacturer identified.

Unlabeled Use Disclosure
This activity may include discussions of products or devices that are not currently approved for use by the Food and Drug Administration (FDA), or are currently investigational.

Supporting Organization
This activity is supported by an educational grant from Novartis Oncology.

Viewing Requirements
This Website requires version 4.x browsers or higher from Microsoft or Netscape. It has been optimized for Microsoft Browsers.